>
Breaking: Joe Kent to Speak at RPI DC Conference!
Painless microneedle tattoos from London startup CipherX
Judge Denies Southern Poverty Law Center's Bid To Dismiss DOJ Indictment
Flock Is Losing Dozens Of Contracts As Citizens Push Back
What could possibly go wrong? Scientists use AI to design new viruses
Dual-motor suitcase drive underpins 3,000-hp hypercar
DoorDash Wins Federal Approval To Fly Its Own Delivery Drones
Shade-Resistant Solar Cells Retain 97% Efficiency After 2,000 Hours of Testing
20 Ancient Engineering SECRETS
Stonehenge Was Reanalyzed by AI -- And the Findings Are Hard to Explain
After Years Of Delays, Aptera Is Finally Preparing To Build Customer Cars
'When you kill it, it doesn't die': the jellyfish that has cracked the secret of immorta
Archer Aviation debuts Halo autonomous VTOL, Thunder's commercial twin
US Telecoms Slide On Starlink Mobile Threat; Bernstein Sees It As A "Jab, But No Knockout Yet**

1. being more-effective tumor responses.
2. the targeted nature of CRISPR-mediated CAR integration into the genome might "prove safer than random integration, which carries the potential risk of generating a harmful mutation," Dr. Maus wrote.
3. It could enable off-the-shelf CAR T cells to be made that need not come from a patient's own T cells. This would enable easier and cheaper manufacture of CAR T cells.
New gene-editing technologies will likely lead to rapid improvement in antigen-targeted T-cell immunotherapies for cancer.
David Edgell, an associate professor of biochemistry at the University of Western Ontario, thinks CRISPR treatments could be available within the next two to three years, with modified T-cells used to treat some types of cancer (there are already clinical trials for lung cancer in China, and a similar one slated to take place at the University of Pennsylvania was approved last June by the National Institutes of Health